Helicobacter pylori-induced inflammation masks the underlying presence of low-grade dysplasia on gastric lesions

Table 2 Endoscopic and histological characteristics of patients before and after Helicobacter pylori eradication

Parameters	Before H. pylori eradication (n = 85)	After H. pylori eradication (n = 85)	P value
Endoscopic atrophy1, n (%)
Absent	5 (5.9)	4 (4.7)	1.0
Antrum	19 (22.4)	19 (22.4)	1.0
Antrum-predominant	18 (21.2)	12 (14.1)	0.23
Corpus-predominant	21 (24.7)	23 (27.1)	0.73
Pan-atrophy	22 (25.9)	27 (31.8)	0.40
OLGA-scale, n (%)
Stage 0	4 (4.7)	4 (4.7)	1.0
Stage 1	22 (25.9)	28 (32.9)	0.31
Stage 2	34 (40)	23 (27.1)	0.07
Stage 3	20 (23.5)	25 (29.4)	0.38
Stage 4	5 (5.9)	5 (5.9)	1.0
EGGIM-scale, n (%)
0-2	47 (55.3)	45 (52.9)	0.76
3-4	21 (24.7)	10 (11.8)	0.03a
5-6	12 (14.1)	21 (24.7)	0.08
7-8	4 (4.7)	4 (4.7)	1.0
9-10	1 (1.2)	5 (5.9)	0.21
OLGIM-scale, n (%)
Stage 0	40 (47.1)	29 (34.1)	0.08
Stage 1	14 (16.5)	17 (20)	0.55
Stage 2	14 (16.5)	14 (16.5)	1.0
Stage 3	13 (15.3)	18 (21.2)	0.32
Stage 4	4 (4.7)	7 (8.2)	0.53
Gastritis at histology2, n (%)
Quiescent	0	81 (95.3)	< 0.0001b
Mild	19 (22.4)	4 (4.7)	0.001b
Moderate	46 (54.1)	0	< 0.0001b
Severe	20 (23.5)	0	< 0.0001b
MALT-hyperplasia, n (%)
Absent	46 (54.1)	82 (96.5)	< 0.0001b
Mild	25 (29.4)	3 (3.5)	< 0.0001b
Moderate	11 (12.9)	0	0.007b
Severe	3 (3.5)	0	0.24
Histological LGD3, n (%)
Absent	70 (82.4)	57 (67.1)	0.02a
On random biopsies	15 (17.6)	9 (10.6)	0.19
On random + on lesions biopsies	0	6 (7)	0.03b
Only on visible lesions	0	13 (15.3)	0.0001b

Data are expressed as number of patients and percentage (in parenthesis).

¹By Kimura and Takemoto[32].

²By Sydney System.

³LGD: Low-grade dysplasia according to World Health Organization classification.

^aBy χ² test.

^bby Fisher’s exact test. H. pylori: Helicobacter pylori; EGGIM: Endoscopic grading of gastric intestinal metaplasia; MALT: Mucosa-associated lymphoid tissue; OLGA: Operative Link on Gastritis Assessment; OLGIM: Operative Link on Gastric Intestinal Metaplasia.